Aetna adds Zepbound to a standard formulary effective October 1, 2026

Aetna has added Zepbound (tirzepatide) to its Standard Control Formulary Choice, listing the drug as a formulary addition in the Endocrine and Metabolic, Antiobesity class effective October 1, 2026 ^[1]. The same update document shows Foundayo (orforglipron) moving from non-preferred to preferred in that class on the same date ^[1].

The Aetna notice is a plan-level formulary document, published in the insurer's formulary update materials ^[1]. It follows CVS Caremark's May 28, 2026 announcement that it would add Zepbound back to its commercial formularies as an additional preferred option beginning October 1, 2026, which the company said increases access to GLP-1 medications at a more affordable price for plan sponsors that elect to cover them ^[2]. CVS Caremark also said it would remove the new-to-market block on Foundayo, described as a new oral GLP-1 therapy, effective June 1, 2026, where plans approve coverage ^[2]. Aetna's pharmacy benefits are administered through CVS Caremark, an affiliate, and Aetna is part of the CVS Health family of companies ^[1].

"We're creating access and options that would not have existed without our leadership in the market," Ed DeVaney, president of CVS Caremark, said in the May announcement ^[2]. CVS Health said its pharmacy benefits manager had approximately 88 million plan members as of March 31, 2026 ^[2].

Coverage can differ by plan. CVS Caremark said plan sponsors that adopt its template formularies retain discretion to customize coverage for their members, so a formulary announcement at the pharmacy benefits manager level does not automatically apply to every plan ^[2]. Aetna's document describes changes to one of its formularies, the Standard Control Formulary Choice, and lists updates as of July 1, 2026, with information subject to change ^[1].

Why it matters for patients

Appearing on a formulary is not the same as being covered without conditions. Aetna's notice states that not all health services are covered, that plan documents provide a complete description of benefits, exclusions, limitations and conditions of coverage, and that the formulary drug list, formulary exclusions, precertification, quantity limit and step therapy lists are all subject to change ^[1].

The notice does not say whether Zepbound will require precertification, step therapy or a quantity limit under this particular plan, so those details have not been disclosed in the formulary update ^[1]. The document also notes that costs depend on factors such as where a member is with a deductible, and that members can log in to their member website on or after October 1, 2026 to search for and estimate the cost of their drugs and find options that may cost less ^[1].

The change applies to tirzepatide, the molecule in Zepbound, and not to semaglutide products such as Ozempic, Wegovy and Rybelsus, which are not part of this specific formulary addition ^[1]. Foundayo is the brand name for orforglipron ^[1][2].

What happens next

October 1, 2026 is the effective date for both the Zepbound addition and the Foundayo tier change on Aetna's Standard Control Formulary Choice, and it is also the date CVS Caremark set for adding Zepbound back to its commercial formularies as a preferred option ^[1][2]. The removal of the new-to-market block on Foundayo took effect June 1, 2026 for plans that approved coverage ^[2].

Aetna's document notes its updates are current as of July 1, 2026 and that information is subject to change, so the published list could be revised before the effective date ^[1]. Whether other insurers and plan sponsors will make the same formulary additions on the same timeline has not been reported.